News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevi Therapeuitcs Names William J. O'Shea to Board and Establishes a Clinical Advisory Board


3/26/2013 8:09:57 AM

Trevi Therapeutics, Inc., (“Trevi”) a drug development company focused on developing Nalbuphine ER for pruritus, announced today that it has named William J. O'Shea to its Board of Directors and established a Clinical Advisory Board to provide clinical and scientific input into the development strategy for Nalbuphine ER.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES